Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
14 hedge funds and large institutions have $2.14M invested in Avenue Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
32% more capital invested
Capital invested by funds: $1.62M → $2.14M (+$520K)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
18% less funds holding
Funds holding: 17 → 14 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.83M |
| 2 |
TSS
Two Sigma Securities
New York
|
+$26K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$26K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$13K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$176K |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$34K |
| 3 |
HF
HRT Financial
New York
|
-$29K |
| 4 |
EL
EMFO LLC
Weston,
Florida
|
-$26K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$23.1K |
ATXI Hedge Fund Activity: Q4 2021 in Review
14 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2021, worth a combined $2.14M — up 32% from $1.62M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ATXI and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Nantahala Capital Management, adding an estimated $1.83M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $176K sold.
- 14 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2021, down from 17 in Q3 2021.
- Funds reported $2.14M of Avenue Therapeutics, Inc. Common Stock stock for Q4 2021, up 32% quarter-over-quarter.
- 2 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2021 and 5 closed out, a net change of -3 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2021 was Nantahala Capital Management, an estimated $1.83M added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2021 was Renaissance Technologies, an estimated $176K sold.
Based on aggregated 13F filings for Q4 2021.